A Review of Data from the EMPEROR Clinical Trials-Jardiance Lecture Version 3

Video Transcription

Video Summary

Dr. Javed Butler, President of the Baylor Scott & White Research Institute and Professor of Medicine at University of Mississippi Medical Center, discusses the clinical data and breakthrough findings from the EMPEROR clinical trials for adults with heart failure. The trials established Jardiance as the first FDA-approved heart failure therapy that reduces the risk of cardiovascular death and hospitalization for heart failure, regardless of left ventricular ejection fraction. Dr. Butler emphasizes the importance of early and aggressive treatment for heart failure due to its high rates of hospitalization and substantial reduction in life expectancy. He highlights the efficacy of Jardiance in reducing the risk of cardiovascular death and hospitalization for heart failure in both HEF-REF and HEF-PEF patients. He also discusses the safety profile and practical considerations for initiating Jardiance treatment in adults with heart failure.

Keywords

Javed Butler

EMPEROR clinical trials

Jardiance

heart failure therapy

cardiovascular death

hospitalization